Event Details: Medicus Presentation at Biotech Showcase

Dr. Raza Bokhari, the Executive Chairman and CEO of Medicus, will deliver an insightful presentation on January 13, 2026, at 10:00 a.m. Pacific time at the Yosemite A venue in the Hilton San Francisco – Union Square. The session will be broadcast live via webcast and archived for later viewing on the company’s website.

Furthermore, Dr. Bokhari and other Medicus executives will be available for one-on-one meetings with institutional investors and potential partners through the partneringONE portal.

Strategic Focus: Phase 2 Development and Partnership Opportunities

Medicus Pharma's core strategy is to advance selected programs through Phase 2 proof-of-concept studies while seeking out licensing and strategic partnerships with established pharmaceutical companies well-suited for late-stage development and commercialization. As data accumulates, the company is positioned to compile decision-grade data packages aligned with its out-licensing objectives.

Advancements in the SkinJect™ Phase 2 Program

Medicus is making notable progress with its SkinJect™ program, a proprietary doxorubicin-based dissolvable microneedle array platform aiming to treat basal cell carcinoma (BCC) effectively and non-invasively. In December 2025, the company completed enrollment of 90 patients in its randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study (SKNJCT-003) at nine clinical sites throughout the United States.

The results from this study, scheduled for topline reporting in Q1 2026, are poised to yield critical insights for an anticipated End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA).

• Interim findings: Initial analysis indicated over 60% clinical clearance during a preliminary review involving more than half of the trial participants.
• Regulatory advances: Recent expansions in the U.S., U.K., and United Arab Emirates support the robust development framework of SkinJect™.

Regulatory Strategy and Expansion Initiatives

Medicus has made significant strides in expanding its clinical and regulatory landscape for the SkinJect™ program. Notable advancements include:

• U.S.: Completion of Phase 2 enrollment for SKNJCT-003.
• U.K: Received essential regulatory approvals to extend the study.
• UAE: Dosing commenced for SKNJCT-004, led by Cleveland Clinic Abu Dhabi.

In September 2025, the FDA offered favorable feedback during a Type C meeting, endorsing the possible application of the 505(b)(2) regulatory pathway for SkinJect™.

Regulatory Optionality and Collaboration Efforts

Medicus has applied for the FDA Commissioner’s National Priority Voucher (CNPV), a program designed to expedite new drug application reviews. If granted, the voucher could facilitate faster approval processes, bolstering Medicus' ongoing strategic partnerships.

In parallel, the company announced a collaboration with Reliant AI Inc. to develop an AI-driven analytics platform that aims to enhance clinical development efficiencies.

Pipeline Expansion and Patient Access Initiatives

The acquisition of Antev Limited in August 2025 has enriched Medicus' pipeline with Teverelix, aimed at addressing advanced prostate cancer. Moreover, collaborations with the Gorlin Syndrome Alliance are underway to facilitate access to SkinJect™ for patients with multiple or inoperable BCCs.

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (NASDAQ: MDCX) is at the forefront of precision-guided biotech, channeling efforts into the swift development of disruptive therapeutic assets across three continents.